Vivos Therapeutics completed a private placement (PIPE) totaling approximately $2.1 million through a Securities Purchase Agreement with V-Co Investors 4 and Bigger Capital Fund. The financing comprised 3,608,496 units at $0.582 per unit, each with one share of Series A Convertible Preferred Stock and a warrant exercisable at $0.456 per share. The company received $1.0 million in cash at closing, and $1.0 million previously funded under a bridge note converted into the PIPE. In connection with the financing, Vivos also entered into a Registration Rights Agreement obligating it to file a resale registration statement within 45 days and seek effectiveness within 90 days, maintaining effectiveness until the securities are freely tradable.

Agreement 1: Vivos Therapeutics Raises $2.1 Million in PIPE With V-Co 4 and Bigger Capital

• Agreement type: Securities Purchase Agreement for private placement (PIPE) of Units (Series A Preferred and Warrants)
• Counterparty: V-Co Investors 4; Bigger Capital Fund
• Signed / Effective: Jun 30 2026 / same
• Duration / Termination: At will
• Reason: Enhance liquidity and fund working capital

Agreement 2: Vivos Therapeutics Grants Resale Registration Rights to PIPE Investors

• Agreement type: Registration Rights Agreement for resale of conversion and warrant shares
• Counterparty: V-Co Investors 4; Bigger Capital Fund
• Signed / Effective: Jun 30 2026 / same
• Duration / Termination: Until all registrable securities are freely tradable
• Reason: Provide investor liquidity and facilitate resale

Original SEC Filing: Vivos Therapeutics, Inc. [ VVOS ] - 8-K - Jul. 07, 2026